Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pharma-Pricing Task Force Launched By US Democrats

XTALKS NEWS

Drug Pricing

The Affordable Drug Pricing Task Force – led by Democrats on the House Committee on Oversight and Government reform announced their intention to hold a press conference today to detail their plan to take “meaningful action to combat the skyrocketing costs of pharmaceuticals.”

Share this!

November 5, 2015 | by Sarah Massey, M.Sc.

Talks surrounding the recent price increases of pharmaceuticals in the US continue to escalate, much to the dismay of drugmakers. According to a group of House Democrats, they are prepared to unveil a pharma-pricing task force to deal with the growing issue.

The announcement follows similar campaign promises made by presidential candidates Hillary Clinton and Senator Bernie Sanders. The Affordable Drug Pricing Task Force – led by Democrats on the House Committee on Oversight and Government reform announced their intention to hold a press conference today to detail their plan to take “meaningful action to combat the skyrocketing costs of pharmaceuticals.”

According to Representative Elijah Cummings, the task force intends to issue subpoenas to Martin Shkreli and Michael Pearson – CEOs of Turing and Valeant respectively – to further investigate each company’s pricing practices following recent price hikes of their drugs. This builds upon Cummings’ generic drug pricing legislation that was included in the budget agreement approved last week.

The legislation will force pharmaceutical manufacturers to provide higher Medicaid rebates when they raise the price of generic medications faster than the rate of inflation. “I believe this [price gouging] unconscionable, and frankly, it’s inexplicable,” said Cummings during the press conference.



“Patients, hospitals, and healthcare providers in all of our districts are affected by this price gouging,” he said. The renewed interest in controlling pharmaceutical prices comes after a number of recent price-hikes, including the 5,000 percent markup of Turing Pharmaceutical’s drug, Daraprim.

“The sudden, aggressive price hikes for a variety of drugs used widely for decades affect patients and health care providers and the overall cost of health care,” commented Senator Susan Collins, the chair of the Special Committee on Aging. According to the task force, they plan on making some new changes to drug pricing legislation that statistics show are popular among the public.

A poll conducted by the Kaiser Family Foundation showed that 77 percent of survey participants – regardless of whether they were Democrats, Republicans or independents – named drug prices as their top health concern. Despite Cummings’ drive to reform drug pricing in the US, analysts are skeptical as to whether those changes are realistic.

Skeptics cite the repeated failures of Medicare price negotiation and drug reimportation as the reason behind their pessimism. The taskforce will also face an uphill battle in dealing with the millions of dollars pharmaceutical companies spend on lobbying, as well the powerful PhRMA industry group in the US capital.

Sources:

WATCH & PARTICIPATE IN THESE WEBINARS 


 

The Use of High Resolution Accurate Mass Spectrometry

Gain Control of Your Packaging Supply Chain


Keywords:  Drug Pricing, US Government, Generics


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
Elderly Patients are Struggling With Too Many Medications and Taking Them As Prescribed

November 4, 2015 - Doctors in the UK have voiced concerns that over half of all patients over 75 years of age are taking too many medications simultaneously, and that they are not always taking the medicines as prescribed..


Self-Disseminating Vaccines and the Fight Against Emerging Infectious Diseases

November 3, 2015 - In the wake of the 2014/2015 Ebola outbreak in West Africa, healthcare professionals are concerned about the world’s ability to handle pandemics and manage emerging infectious diseases.


Mainstay Medical Applies for CE Mark and FDA Approval for Their Neuromodulation Implant

November 3, 2015 - Mainstay Medical is seeking both European and North American approval for its neuromodulation device for chronic lower back pain.


LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.